Advanced search
Publication Cover
Human Vaccines & Immunotherapeutics Volume 13, 2017 - Issue 12: The International Society for Vaccines 2016 Annual Congress, Boston, Oct. 2-4, 2016
Submit an article Journal homepage
1,141
Views
3
CrossRef citations to date
0
Altmetric
Research Papers

Application of replication-defective West Nile virus vector to non-flavivirus vaccine targets

Maryann Giel-MoloneyR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Michael VaineR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Linong ZhangR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Mark ParringtonR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Beata GajewskaR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Thorsten U. VogelR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Svetlana O. PougatchevaR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Xiaochu DuanR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Timothy FarrellR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Irina UstyugovaR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Sanjay PhogatR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
,
Harry KleanthousR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USA
&
Konstantin V. PugachevR&D Discovery US, Sanofi Pasteur, Cambridge, MA, USACorrespondence[email protected]
 show all
Pages 2982-2986 | Received 02 May 2017, Accepted 28 Aug 2017, Published online: 18 Oct 2017

References

  • Mason PW, Shustov AV, Frolov I. Production and characterization of vaccines based on flaviviruses defective in replication. Virology. 2006;351:432-43.[https://doi.org/10.1016/j.virol.2006.04.003]. PMID:16712897
  • Suzuki R, Fayzulin R, Frolov I, Mason PW. Identification of mutated cyclization sequences that permit efficient replication of West Nile virus genomes: Use in safer propagation of a novel vaccine candidate. J Virol. 2008;82:6942-51.[https://doi.org/10.1128/JVI.00662-08]. PMID:18480453
  • Rumyantsev AA, Giel-Moloney M, Liu Y, Gao QS, Zhang ZX, Catalan J, Frolov I, Almond J, Kleanthous H, Pugachev KV. Characterization of the RepliVax platform for replication-defective flavivirus vaccines. Vaccine. 2011;29:5184-94.[https://doi.org/10.1016/j.vaccine.2011.05.032]. PMID:21620917
  • Rumyantsev AA, Goncalvez AP, Giel-Moloney M, Catalan J, Liu Y, Gao QS, Almond J, Kleanthous H, Pugachev KV. Single-dose vaccine against tick-borne encephalitis. Proc Natl Acad Sci USA. 2013;110:13103-8.[https://doi.org/10.1073/pnas.1306245110]. PMID:23858441
  • Monath TP, Cetron MS, Teuwen D. Yellow fever vaccine. In: Plotkin S, Orenstein W, Offit P, editors. Vaccines. 5th ed. Philadelphia (PA): Saunders/Elsevier; 2008. p. 959-1055.
  • Pijlman GP, Suhrbier A, Khromykh AA. Kunjin virus replicons: An RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther. 2006;6:135-45.[https://doi.org/10.1517/14712598.6.2.135] PMID:16436039
  • Kahn JS, Schnell MJ, Buonocore L, Rose JK. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion. Virology. 1999;254:81-91.[https://doi.org/10.1006/viro.1998.9535]. PMID:9927576
  • Li X, Sambhara S, Li CX, Ewasyshyn M, Parrington M, Caterini J, James O, Cates G, Du RP, Klein M. Protection against respiratory syncytial virus infection by DNA immunization. J Exp Med. 1998;188:681-8.[https://doi.org/10.1084/jem.188.4.681]. PMID:9705950
  • Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol. 1969;89:422-34.[https://doi.org/10.1093/oxfordjournals.aje.a120955]. PMID:4305198
  • Tripp RA, Tompkins SM. Virus-vectored influenza virus vaccines. Viruses. 2014;6:3055-79.[https://doi.org/10.3390/v6083055]. PMID:25105278
  • Carter DM, Darby CA, Lefoley BC, Crevar CJ, Alefantis T, Oomen R, Anderson SF, Strugnell T, Cortes-Garcia G, Vogel TU, et al. Design and characterization of a computationally optimized broadly reactive hemagglutinin vaccine for H1N1 influenza viruses. J Virol. 2016;90:4720-34.[https://doi.org/10.1128/JVI.03152-15]. PMID:26912624
  • Haensler J, Probeck P, Su J, Piras F, Dalencon F, Cotte JF, Chambon V, Iqbal SM, Hawkins L, Burdin N. Design and preclinical characterization of a novel vaccine adjuvant formulation consisting of a synthetic TLR4 agonist in a thermoreversible squalene emulsion. Int J Pharm. 2015;486:99-111.[https://doi.org/10.1016/j.ijpharm.2015.03.028]. PMID:25794609
  • Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209-20.[https://doi.org/10.1056/NEJMoa0908492]. PMID:19843557
  • Mebatsion T, Conzelmann KK. Specific infection of CD4+ target cells by recombinant rabies virus pseudotypes carrying the HIV-1 envelope spike protein. Proc Natl Acad Sci USA. 1996;93:11366-70.[https://doi.org/10.1073/pnas.93.21.11366]. PMID:8876141
  • Dietzschold B, Wiktor TJ, Macfarlan R, Varrichio A. Antigenic structure of rabies virus glycoprotein: Ordering and immunological characterization of the large CNBr cleavage fragments. J Virol. 1982;44:595-602. PMID:6183450

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.